AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02331082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Electronic Medical Record
Description: Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
Study NCT02331082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solar-powered electrical supply
Description: As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
Study NCT02331082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based financing
Description: As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
Study NCT02331082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Existing healthcare system
Description: This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
Study NCT03816930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical cord usage
Description: Due to the retraction procedures, same preparation conditions will be obtained.
Study NCT02550184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focused ultrasonographic examination.
Description: Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
Study NCT02550184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused ultrasonographic examination.
Description: Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
Study NCT01541475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion, Escitalopram
Description: Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
Study NCT01541475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
Study NCT00490451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
Study NCT02346162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI \</=25, and when pregnant, weight gain within IOM guidelines.
Study NCT02346162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
Study NCT00950664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport® (abobotulinumtoxinA)
Description: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
Study NCT00950664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox® (onabotulinumtoxinA)
Description: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
Study NCT02351505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT02351505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02351505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01582425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01582425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: oral
Study NCT01083303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weaning Preterm Infants from an incubator
Description: Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
Study NCT01083303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weaning Preterm Infants from an incubator
Description: Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
Study NCT03269045 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ORL-1B
Description: Oral ORL-1B
Study NCT03173833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAGO questionnaire outcome
Description: Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
Study NCT04209751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool removal
Description: Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
Study NCT04458298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: OP-101 infusion will be administered intravenously.
Study NCT04458298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo infusion will be administered intravenously.
Study NCT01317862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter, Prostaglandins
Description: 16 French foley catheter 10mg dinoprostone vaginal insert
Study NCT00050609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 5 mg tadalafil tablet taken by mouth once a day for 8 weeks
Study NCT00050609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet taken by mouth once a day for 8 weeks
Study NCT00050609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet taken by mouth once a day for 8 weeks
Study NCT03000907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Diet and physical exercises
Study NCT05309798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening Fasting
Description: Participants will undertake acute evening fasting (feeding between 8am-4pm) for one day. After which they will attend the laboratory, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
Study NCT05309798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Fasting
Description: Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm). After which, participants will visit the laboratory the following day, after a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
Study NCT05309798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm). After which, participants will visit the laboratory the following day, after a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
Study NCT03831841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise programe
Description: An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
Study NCT01508702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 400 mg QD
Study NCT01508702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo QD
Study NCT01202929 — intervention group
Intervention type: PROCEDURE
Intervention: High Resolution Manometry
Description: High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
Study NCT04845100 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Animal Assisted Activity Program
Description: Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)
Study NCT04845100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Assisted Activity Program
Description: Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)
Study NCT03222206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 1. Medicate salsalate 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month
Study NCT03222206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Medicate placebo 2g/day after run-in period~2. Check side effect after 1 month and Control dosage (2g/day or 3g/day)~3. Check side effect after 2 month
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone capsules, 2.5 mg
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 5 mg
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 10 mg
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 20 mg
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 40 mg
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 80 mg
Study NCT02255422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omaveloxolone capsules, 160 mg
Study NCT04967937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening, resistance exercise, plyometric and dynamic movement training
Description: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
Study NCT03536988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAMIS-IPAA
Description: In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
Study NCT03536988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap-IPAA
Description: In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
Study NCT01950000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT01950000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01565733 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
Study NCT02595151 — intervention group
Intervention type: DEVICE
Intervention: CLE
Description: The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
Study NCT04539639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
Study NCT04539639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
Study NCT04539639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
Study NCT04539639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide
Description: * Arms A\&B: 1.8 g/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: * Arms A\&B: 100 mg/m\^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 400 mg/m\^2 daily on days -4, -3, and -2 every 21 days~* Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age >36 mos.) approx. hour 75 on days -5, -4, and -3
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mesna
Description: * Arms A\&B: 1.8 g/m\^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~* Arm C: 2000 mg/m\^2 IV daily on Days 1-3 every 14 days for 2 cycles
Study NCT01505569 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: G-CSF
Description: * Arms A\&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (>) 1,000/mm\^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is >2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3~* Arm C: 10 μg/kg SQ daily beginning 6 hours after ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.~* Arm D: Beginning day +1 following hematopoietic cell reinfusion, patients receive filgrastim at a dose of 5mcg/kg SQ once daily (or 5mcg/Kg IV either daily or twice daily, per institutional preference)~* Arm E: 5 micrograms/kg/dose beginning on Day 0 and continue per institutional preference
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Arm A: 50 mg/m\^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Arm A: 250 mg/m\^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m\^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age >36 mos.) approx. hour 72 on days -5, -4, and -3
Study NCT01505569 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Autologous stem cell infusion
Description: Arms A, B \& C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.~Arm D: On day 0, peripheral blood hematopoietic progenitor cells (PHPCs) or bone marrow cells will be thawed and re-infused about 72 hours following completion of the last dose of chemotherapy.~Arm E: stem cells will be infused on Day 0 of Consolidation. Where the DMSO volume in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over 2 days to meet this standard.
Study NCT01505569 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.~Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose.
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m\^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
Study NCT01505569 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Leukapheresis
Description: Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-seizure prophylaxis
Description: Arm E: Lorazepam OR Levetaracetam~* Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~* Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg.
Study NCT01505569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ursodiol
Description: Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
Study NCT05133011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue base reduction surgery
Description: Tongue base reduction surgery which remove the extra soft tissue of the base of the tongue and soft palate in this study
Study NCT00651066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1
Description: 3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
Study NCT00651066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2
Description: 3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
Study NCT04319133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Doing fasting 2 days a week within 8 weeks
Study NCT04511247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagicTouch PTA Sirolimus drug coated balloon
Description: For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
Study NCT04511247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA balloon
Description: For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
Study NCT03050242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery